Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL260090 | 1.00 | ADORA3 (0.39) | ADORA3ADORA2AHIF1AADORA1TP53 | |
| SCHEMBL2101890 | 0.91 | ADORA3 (0.42) | ADORA3ADORA2AHIF1AADORA1TP53 | |
| SCHEMBL2101900 | 0.91 | ADORA3 (0.42) | ADORA3ADORA2AHIF1AADORA1TP53 | |
| SCHEMBL260214 | 0.87 | ADK (0.43) | ADORA3HIF1AADORA1RXFP1 | |
| SCHEMBL260216 | 0.87 | ADK (0.43) | ADORA3HIF1AADORA1RXFP1 | |
| SCHEMBL259660 | 0.85 | HIF1A (0.40) | ADORA3ADORA2AHIF1AADORA1TSHR | |
| SCHEMBL259659 | 0.85 | HIF1A (0.40) | ADORA3ADORA2AHIF1AADORA1TSHR | |
| SCHEMBL260316 | 0.83 | SLC29A1 (0.44) | ADORA3ADORA2AHIF1AADORA1TSHR | |
| SCHEMBL2102610 | 0.83 | ADORA3 (0.41) | ADORA3ADORA2AHIF1AADORA1TP53 | |
| SCHEMBL260317 | 0.83 | SLC29A1 (0.44) | ADORA3ADORA2AHIF1AADORA1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130078218-A1 | HEPATITIS C THERAPIES | BIOCRYST PHARMACEUTICALS, INC. | 2013-03-28 | — | — | US | claimed |
| EP-2537520-A1 | Hepatics C therapies | Biocryst Pharmaceuticals, Inc. (US) | 2012-12-26 | — | — | EP | claimed |
| US-8163703-B2 | Hepatitis C therapies | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | claimed |
| US-20100143300-A1 | HEPATITIS C THERAPIES | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2010-06-10 | — | — | US | claimed |
| US-7514410-B2 | Hepatitis C therapies | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-04-07 | — | — | US | claimed |
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | claimed |
| US-20060234963-A1 | Hepatitis C therapies | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2006-10-19 | — | — | US | claimed |
| US-20130078218-A1 | HEPATITIS C THERAPIES | BIOCRYST PHARMACEUTICALS, INC. | 2013-03-28 | — | — | US | disclosed |
| EP-2537520-A1 | Hepatics C therapies | Biocryst Pharmaceuticals, Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| US-20120213735-A1 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-8163703-B2 | Hepatitis C therapies | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8133870-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20100143300-A1 | HEPATITIS C THERAPIES | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2010-06-10 | — | — | US | disclosed |
| US-7514410-B2 | Hepatitis C therapies | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-7429571-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| EP-1863500-A2 | HEPATITIS C THERAPIES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20060234963-A1 | Hepatitis C therapies | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2006-10-19 | — | — | US | disclosed |
| WO-2006104945-A2 | HEPATITIS C THERAPIES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-10-05 | — | — | WO | disclosed |
| US-20060165655-A1 | Therapeutic furopyrimidines and thienopyrimidines | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | DPYD, TYMP, TYMS | ADORA3 1767/4885ADORA2A 2082/4885HIF1A 2705/4885 |
| US-20130078218-A1 | HEPATITIS C THERAPIES | HAVCR2, FABP1, LIPC | ADORA3 802/4885ADORA2A 1148/4885HIF1A 636/4885 |
| US-20060234963-A1 | Hepatitis C therapies | HAVCR2, FABP1, LIPC | ADORA3 802/4885ADORA2A 1148/4885HIF1A 636/4885 |
| US-20060165655-A1 | Therapeutic furopyrimidines and thienopyrimidines | DPYD, TYMP, TYMS | ADORA3 1767/4885ADORA2A 2082/4885HIF1A 2705/4885 |
| US-20120213735-A1 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | DPYD, TYMP, TYMS | ADORA3 1767/4885ADORA2A 2082/4885HIF1A 2705/4885 |
| US-20100143300-A1 | HEPATITIS C THERAPIES | HAVCR2, FABP1, LIPC | ADORA3 802/4885ADORA2A 1148/4885HIF1A 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.